Clinical Trial Update: Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial comparing standard-dose versus high-dose imatinib mesylate in patients with chronic phase Philadelphia chromosome–positive chronic myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia | Phase 4 | Status: COMPLETED